Pharmaceuticals
- Share via
* BASF, Europe’s biggest chemical manufacturer, is considering bids of at least $6 billion for its Knoll drug unit, people familiar with the situation said. Analysts said bidders, which could include Bristol-Myers Squibb Co. and Eli Lilly & Co., are said to attracted to Knoll’s rheumatoid arthritis drug D2E7.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
